{"filing":{"accession_number":"0001005286-26-000036","cik":"0001005286","ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. \\DE\\","form":"8-K","filing_date":"2026-09-29","report_date":"2026-09-24","primary_document":"lfcr-20260924.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528626000036/lfcr-20260924.htm"},"events":[{"id":35756,"run_id":32952,"accession_number":"0001005286-26-000036","anchor_item_number":"1.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The disclosure describes an amendment to a material contract manufacturing agreement with Alcon that extends the term through 2034, establishes minimum purchase obligations, and imposes non-compete restrictions on Lifecore. While this is a material definitive agreement under Item 1.01, it does not constitute a merger, acquisition, disposition, or change of control (ma_activity), nor does it fit other specific event categories. The amendment is a significant operational and commercial arrangement that would affect investor assessment of the company's revenue stability and strategic flexibility, making it material and best classified as an operational event.","company_name":"LIFECORE BIOMEDICAL, INC. \\DE\\","ticker":"LFCR","filing_date":"2026-09-29","form":"8-K","submitted_at":null,"items":[{"id":39923,"accession_number":"0001005286-26-000036","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure describes an amendment to a material contract manufacturing agreement with Alcon that extends the term through 2034, establishes minimum purchase obligations, and imposes non-compete restrictions on Lifecore. While this is a material definitive agreement under Item 1.01, it does not constitute a merger, acquisition, disposition, or change of control (ma_activity), nor does it fit other specific event categories. The amendment is a significant operational and commercial arrangement that would affect investor assessment of the company's revenue stability and strategic flexibility, making it material and best classified as an operational event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T20:13:57.573128+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39923,"accession_number":"0001005286-26-000036","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure describes an amendment to a material contract manufacturing agreement with Alcon that extends the term through 2034, establishes minimum purchase obligations, and imposes non-compete restrictions on Lifecore. While this is a material definitive agreement under Item 1.01, it does not constitute a merger, acquisition, disposition, or change of control (ma_activity), nor does it fit other specific event categories. The amendment is a significant operational and commercial arrangement that would affect investor assessment of the company's revenue stability and strategic flexibility, making it material and best classified as an operational event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T20:13:57.573128+00:00","company_name":"LIFECORE BIOMEDICAL, INC. \\DE\\","ticker":"LFCR","filing_date":"2026-09-29"}]}